Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Sales (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Return on Sales data on record, last reported at 182.9% in Q3 2025.

  • For Q3 2025, Return on Sales fell 9660.0% year-over-year to 182.9%; the TTM value through Sep 2025 reached 86.33%, down 4721.0%, while the annual FY2024 figure was 35.0%, 9504.0% up from the prior year.
  • Return on Sales reached 182.9% in Q3 2025 per BTAI's latest filing, down from 165.37% in the prior quarter.
  • Across five years, Return on Sales topped out at 4496.0% in Q1 2022 and bottomed at 253.48% in Q1 2023.
  • Average Return on Sales over 4 years is 207.11%, with a median of 80.14% recorded in 2025.
  • Peak YoY movement for Return on Sales: plummeted -474948bps in 2023, then soared 20739bps in 2024.
  • A 4-year view of Return on Sales shows it stood at 230.53% in 2022, then surged by 73bps to 62.31% in 2023, then surged by 40bps to 37.4% in 2024, then plummeted by -389bps to 182.9% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 182.9% in Q3 2025, 165.37% in Q2 2025, and 80.14% in Q1 2025.